文献速递脊柱关节炎

MK2抑制剂CC-99677治疗强直性脊柱炎的II期随机安慰剂对照研究

Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis.
PubMed 文献 · RMD Open · 2026-05-21

这项II期随机双盲安慰剂对照试验评估了MK2抑制剂CC-99677(150mg和60mg每日一次)在147例活动性强直性脊柱炎患者中的疗效与安全性。12周时ASAS20应答率在各组间无显著差异,研究因中期分析无效而终止,提示MK2抑制不足以产生显著临床获益。

要点

  • CC-99677 150mg和60mg组12周ASAS20应答率与安慰剂组无显著差异。
  • 研究因中期分析显示无效而提前终止,主要停药原因为研究终止。
  • 治疗总体耐受良好,但血清促炎细胞因子抑制轻微。

核心结论

  • MK2抑制剂CC-99677在强直性脊柱炎患者中未能产生显著临床获益。

研究设计与样本

  • II期多中心随机双盲安慰剂对照试验,147例活动性强直性脊柱炎患者按1:1:1随机接受CC-99677 150mg、60mg或安慰剂每日一次。

主要发现

  • 12周ASAS20应答率:60mg组51.2%,150mg组56.1%,安慰剂组48.8%;ASAS40应答率分别为25.6%、34.1%和22.0%。
  • 次要终点未见显著组间差异,活跃治疗组MRI脊柱和骶髂关节炎症评分有改善趋势但血清促炎细胞因子抑制轻微。
  • 123例(83.7%)完成双盲安慰剂对照期治疗,主要停药原因为基于中期分析无效的研究终止。

关键数值与推荐

  • 入选标准为符合修订纽约标准的活动性强直性脊柱炎,BASDAI≥4且总背痛≥4,且对至少2种NSAIDs反应不佳、未使用过生物制剂。
  • 主要终点为12周ASAS20应答率。

临床怎么用

  • 不推荐将MK2抑制剂CC-99677用于强直性脊柱炎治疗,因未显示优于安慰剂的临床疗效。

局限性

  • 研究因中期分析无效提前终止,可能影响统计效能和次要终点解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: CC-99677 (BMS-986371) is a novel, small-molecule covalent inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MK2). We aimed to evaluate the dose-dependent efficacy and safety of CC-99677 compared with placebo in subjects with ankylosing spondylitis (AS). METHODS: This was a phase II, multicentre, randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of CC-99677 in subjects with AS. Subjects were randomised 1:1:1 to once-daily CC-99677 150 mg, CC-99677 60 mg or placebo. Main inclusion criteria were fulfilment of the modified New York criteria for AS, active symptoms (Bath Ankylosing Spondylitis Disease Activity Index ≥4 and total back pain ≥4) despite ≥2 non-steroidal anti-inflammatory drugs and naïve to biologic disease-modifying anti-inflammatory drugs. The primary end point was Assessment of SpondyloArthritis international Society 20% improvement criteria (ASAS20) response at 12 weeks. RESULTS: 147 subjects were enrolled and 123 (83.7%) subjects completed treatment in the double-blind, placebo-controlled period. The main reason for discontinuation was study termination based on futility at interim analysis. Baseline characteristics were typical of an AS trial population. Treatment with CC-99677 was generally well-tolerated. ASAS20 and ASAS40 at week 12 were 51.2% and 25.6% in the CC-99677 60 mg group, 56.1% and 34.1% in the 150 mg group and 48.8% and 22.0% in the placebo group. No significant treatment group differences were noted for secondary end points. There were trends in active treatment groups for improvement in MRI spine and sacroiliac joint inflammation scores but minimal inhibition of pro-inflammatory cytokines in serum. CONCLUSIONS: Inhibition of MK2 by CC-99677 was insufficient to lead to significant clinical benefits in AS. TRIAL REGISTRATION NUMBER: NCT04947579.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Maksymowych WP, Yeshokumar A, Cerullo E, et al. Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis. RMD Open. 2026. PMID: 42167889. doi:10.1136/rmdopen-2025-006527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。